Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

612
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
612
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

92
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
92
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

671
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
671
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

108
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
108
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

248
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
248
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

151
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
151

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenicity and reactogenicity of the adjuvanted respiratory syncytial virus vaccine in patients with chronic kidney disease.

Clinical kidney journal·2026
Same author

Positive net antiviral benefit of bexarotene against patient-derived archetype and rearranged BK polyomavirus isolates.

Antiviral research·2026
Same author

The Role of Cytomegalovirus-specific Immunoglobulins as Modulators of Antigen-specific T-cell Expansion In Vitro.

Transplantation direct·2025
Same author

Urinary Dickkopf-3 Predicts GFR Loss in the General Population.

Kidney international reports·2025
Same author

Dickkopf-3 (DKK3) and the Progression of Diabetic Kidney Disease in Primary Health Care.

Diabetes·2025
Same author

Cellular and humoral immunogenicity of respiratory syncytial virus vaccination in solid organ transplant recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
See all related articles

Related Experiment Video

Updated: Nov 20, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.7K

[Symptom control in heart failure patients - how to handle GFR decrease and hyperkalaemia].

Vincent Brandenburg1, Johann Bauersachs2, Michael Böhm3

  • 1Klinik für Kardiologie, Nephrologie und Internistische Intensivmedizin, Rhein-Maas-Klinikum, Würselen.

Deutsche Medizinische Wochenschrift (1946)
|January 22, 2021
PubMed
Summary
This summary is machine-generated.

Optimizing medication for heart failure with reduced ejection fraction is crucial. This consensus provides a practical guide for managing decreased kidney function and high potassium levels, common issues that often lead to stopping heart failure drugs.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

478
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.7K

Related Experiment Videos

Last Updated: Nov 20, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.7K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

478
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.7K

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Optimized medication in heart failure with reduced ejection fraction (HFrEF) improves symptoms and survival.
  • Renin-angiotensin-aldosterone-system (RAAS) inhibitors are fundamental to HFrEF management.
  • Reduced glomerular filtration rate (GFR) and hyperkalemia are frequent reasons for dose reduction or discontinuation of RAAS inhibitors.

Purpose of the Study:

  • To establish a consensus on managing decreased GFR in HFrEF patients on RAAS inhibitors.
  • To provide a pragmatic approach for handling hyperkalemia in HFrEF patients treated with RAAS inhibitors.
  • To guide clinicians in optimizing RAAS inhibitor therapy despite adverse events.

Main Methods:

  • Expert consensus development involving cardiologists and nephrologists.
  • Review of current evidence and clinical guidelines for RAAS inhibitor management.
  • Development of a pragmatic, stepwise approach for managing GFR and potassium levels.

Main Results:

  • A consensus was reached on criteria for monitoring GFR and potassium.
  • A practical strategy for adjusting RAAS inhibitor doses was outlined.
  • Recommendations for initiating and titrating RAAS inhibitors were established.

Conclusions:

  • Effective management of GFR and potassium levels allows for continued RAAS inhibitor therapy in most HFrEF patients.
  • This consensus provides a framework for optimizing heart failure treatment and reducing mortality.
  • Collaboration between cardiology and nephrology is key to overcoming treatment barriers.